TL;DR
Major US health insurers are navigating a high-stakes environment where massive regulatory rate relief and strategic portfolio pruning are successfully offsetting persistent legislative threats. While vertically integrated giants face intensifying federal and state crackdowns on pharmacy ownership, payers are stabilizing their margins by exiting volatile government-sponsored programs and capturing lucrative federal risk-adjustment receivables. Ultimately, the industry is proving its resilience by turning regulatory complexity and market contraction into highly calculated profitability engines.
The Structural Assault on Vertical Integration and PBM Economics
Federal and state policymakers are launching structural attacks on the core profit engine of integrated insurers, forcing defensive business-model pivots and aggressive legal counter-offensives. Bipartisan sponsors reintroduced the Patients Before Monopolies Act, which slashes the pharmacy divestment window to a single year and imposes a 10% monthly profit penalty on non-compliant insurers Regulatory and Legislative Crackdown on PBMs and Vertical Integration. Simultaneously, states like Tennessee are enacting structural bans like the FAIR Rx Act, which prohibits joint pharmacy benefit manager (PBM) and pharmacy ownership above a 5% threshold [Regulatory and Legislative Crackdown on PBMs and Vertical Integration](/topics/019e89d0-893e-7d00-a5cf-ca1051e66e9d/notes/regulatory-pbm-reform-vertical-integration-cracks].
"On May 8, 2026, Optum Rx, Inc. (a PBM) and Emisar Pharma Services (an affiliated GPO) sued to block enforcement of California S.B. 41... arguing that key provisions of the law are preempted by ERISA." — Regulatory and Legislative Crackdown on PBMs and Vertical Integration
, citing Mintz Levin
This multi-front battle shows that the highly integrated managed care model is no longer politically safe. By combining federal preemption litigation with proactive pivots to flat-fee pricing, integrated payers are scrambling to protect their pharmacy-driven margins before structural divestitures are legally mandated.
What to watch: Watch whether Optum Rx's lawsuit against California's S.B. 41 successfully establishes ERISA preemption as an impenetrable shield against state-level pharmacy divestment laws.
Strategic Portfolio De-risking and the Flight to Commercial Stability
Major managed care companies are aggressively purging volatile, government-sponsored business lines in favor of stable, commercial pharmacy and specialty care services. On its first-quarter earnings call, Cigna confirmed that its Evernorth division generated the vast majority of its revenue—amounting to 85.3% of the total enterprise—while announcing a complete exit from the individual ACA exchange market for the 2027 plan year Cigna's Pivot to Evernorth and the De-Risked Commercial Employer Focus.
"Cigna will exit the individual market for the 2027 plan year as the segment faces renewed instability..." — Cigna's Pivot to Evernorth and the De-Risked Commercial Employer Focus
, citing Fierce Healthcare
By systematically offloading Medicare Advantage and exiting individual exchanges, Cigna has successfully transitioned into a high-margin, capital-light pharmacy and commercial services business. This shields the company's bottom line from regulatory rate shocks and medical utilization spikes, transforming it into a services powerhouse with a smaller commercial insurance wrapper.
What to watch: Watch for the outcome of Cigna's strategic review of its eviCore unit, which could signal a broader industry retreat from highly scrutinized prior authorization businesses.
Regulatory Relief and Arbitrage in Government-Sponsored Programs
While public-facing regulatory actions appear hostile, behind-the-scenes rate adjustments and government risk-mitigation programs are delivering massive financial windfalls to insurers. In the finalized Calendar Year rate announcement, federal regulators locked in an average rate increase of 2.48%, delivering a massive $13 billion cash injection to plans Medicare Advantage Star Ratings: CMS Voluntary Redo and the Sector-Wide Litigation Battlefront. Meanwhile, Centene is turning a severe membership contraction into a calculated margin play by leveraging the ACA's risk adjustment program Centene: Marketplace Risk Adjustment and the June Wakely Consulting Catalyst
.
"The silver tier remaining membership really followed the golden rule of risk pools, that when it shrinks it becomes more morbid... Centene had previously expected to be hit with a risk adjustment payment in 2026 and now expects to receive money through the pathway." — Centene: Marketplace Risk Adjustment and the June Wakely Consulting Catalyst
, citing HealthworksAI
The multi-billion dollar rate reversal and the lucrative mechanics of risk-adjustment pools demonstrate that managed care profitability remains deeply protected by federal frameworks. Even when insurers lose millions of members, sophisticated risk-mitigation rules allow them to capture substantial receivables that offset underwriting losses.
What to watch: Watch for the final federal risk adjustment report in late June to see if Centene's calculated gamble translates into its targeted 4 percent Marketplace margins.
What surprised us
- CMS’s voluntary recalculation was a calculated head-fake. Rather than applying the Clover Health court criteria industry-wide, CMS issued a highly restrictive recalculation that conceded only on narrow data-source authority while refusing to budge on challenged rulemaking Medicare Advantage Star Ratings: CMS Voluntary Redo and the Sector-Wide Litigation Battlefront
- Humana staged a massive stock recovery despite staring down a utilization squeeze. Even as rising senior utilization and high-cost specialty drugs compressed margins, Humana's stock surged 121.9% over three months to a new 52-week high of $383.84 Humana's Medicare Advantage Margin Compression and the 2027 Benefit Cliff
- Losing over a third of your customers can actually unlock a margin tailwind. Under normal business logic, Centene’s 36.4% year-over-year drop in Marketplace enrollment would be a disaster Centene: Marketplace Risk Adjustment and the June Wakely Consulting Catalyst